C Pericay1, X Serra-Aracil2, J Ocaña-Rojas3, L Mora-López2, E Dotor3, A Casalots4, A Pisa3, E Saigí3. 1. Medical Oncology Service, Parc Tauli University Hospital, Universidad Autonoma de Barcelona, Parc Tauli, no. 1, 08208, Sabadell, Barcelona, Spain. cpericay@gmail.com. 2. Coloproctology Unit, General and Digestive Surgery Service, Parc Tauli University Hospital, Universidad Autonoma de Barcelona, Sabadell, Barcelona, Spain. 3. Medical Oncology Service, Parc Tauli University Hospital, Universidad Autonoma de Barcelona, Parc Tauli, no. 1, 08208, Sabadell, Barcelona, Spain. 4. Pathology Service, Parc Tauli University Hospital, Universidad Autonoma de Barcelona, Sabadell, Barcelona, Spain.
Abstract
PURPOSE: Preoperative chemoradiotherapy and local excision via transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer achieve promising results in selected patients. We describe our long-term follow-up experience with this combination, and evaluate complete clinical and pathological responses, local recurrence and overall survival. METHODS: The prospective observational follow-up study carried out since 2007. Out of 476 consecutive patients treated with TEM, we selected those with adenocarcinoma of low or moderate grade of differentiation, clinical stages T2-superficial T3,N0,M0, who refused radical surgery. Preoperative chemoradiotherapy comprised 5-fluorouracil or capecitabine combined with radiotherapy at a dose of 50.4 Gy. TEM was performed after 8 weeks. Complications were recorded and long-term follow-up was conducted. RESULTS: Fifteen patients undergoing preoperative chemoradiotherapy and TEM (median age 76 years, 95 % CI 70.3-80.4, and median follow-up 38 months, 95 % CI 20-44) were studied. No local recurrence was observed, and only one patient (6.7 %) presented systemic relapse. The overall survival was 76 %. Complete clinical response was achieved in seven patients (46.7 %) and complete pathological response in four (26.7 %). With regard to toxicity associated with neoadjuvant treatment, four patients (26.7 %) developed grade 3 adverse effects; no grade 4 or 5 adverse effects were observed. There was no postoperative mortality. CONCLUSIONS: The results of our study, with a response rate of 26.7 % and without local relapse, support the treatment of T2-3s,N0,M0 of rectal cancer with preoperative chemoradiotherapy and local excision (TEM).
PURPOSE: Preoperative chemoradiotherapy and local excision via transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer achieve promising results in selected patients. We describe our long-term follow-up experience with this combination, and evaluate complete clinical and pathological responses, local recurrence and overall survival. METHODS: The prospective observational follow-up study carried out since 2007. Out of 476 consecutive patients treated with TEM, we selected those with adenocarcinoma of low or moderate grade of differentiation, clinical stages T2-superficial T3,N0,M0, who refused radical surgery. Preoperative chemoradiotherapy comprised 5-fluorouracil or capecitabine combined with radiotherapy at a dose of 50.4 Gy. TEM was performed after 8 weeks. Complications were recorded and long-term follow-up was conducted. RESULTS: Fifteen patients undergoing preoperative chemoradiotherapy and TEM (median age 76 years, 95 % CI 70.3-80.4, and median follow-up 38 months, 95 % CI 20-44) were studied. No local recurrence was observed, and only one patient (6.7 %) presented systemic relapse. The overall survival was 76 %. Complete clinical response was achieved in seven patients (46.7 %) and complete pathological response in four (26.7 %). With regard to toxicity associated with neoadjuvant treatment, four patients (26.7 %) developed grade 3 adverse effects; no grade 4 or 5 adverse effects were observed. There was no postoperative mortality. CONCLUSIONS: The results of our study, with a response rate of 26.7 % and without local relapse, support the treatment of T2-3s,N0,M0 of rectal cancer with preoperative chemoradiotherapy and local excision (TEM).
Entities:
Keywords:
Preoperative chemoradioterapy; Rectal cancer; TEM
Authors: Glenda G Callender; Prajnan Das; Miguel A Rodriguez-Bigas; John M Skibber; Christopher H Crane; Sunil Krishnan; Marc E Delclos; Barry W Feig Journal: Ann Surg Oncol Date: 2009-10-22 Impact factor: 5.344
Authors: Xavier Serra-Aracil; Laura Mora-Lopez; Manel Alcantara-Moral; Aleidis Caro-Tarrago; Carlos Javier Gomez-Diaz; Salvador Navarro-Soto Journal: World J Gastroenterol Date: 2014-09-07 Impact factor: 5.742
Authors: Chang Sik Yu; Hae Ran Yun; Eung Jin Shin; Kang Yong Lee; Nam Kyu Kim; Seok-Byung Lim; Seong Taek Oh; Sung-Bum Kang; Won Joon Choi; Woo Yong Lee Journal: Am J Surg Date: 2013-07-09 Impact factor: 2.565